Streptococcus pyogenes (group A Streptococcus) causes diseases ranging from mild pharyngitis to severe invasive infections. The N-terminal fragment of streptococcal M protein elicits protective antibodies and is an attractive vaccine target. However, this N-terminal fragment is hypervariable: there are more than 200 different M types. In this study, an intranasal live bacterial vaccine comprising 10 strains of Lactococcus lactis, each expressing one N-terminal fragment of M protein, has been developed. Live bacterial-vectored vaccines cost less to manufacture because the processes involved are less complex than those required for production of protein subunit vaccines. Moreover, intranasal administration does not require syringes or specialized personnel. Evaluation of individual vaccine types (M1, M2, M3, M4, M6, M9, M12, M22, M28 and M77) showed that most of them protected mice against challenge with virulent S. pyogenes. All 10 strains combined in a 10-valent vaccine (MÂ10) induced serum and bronchoalveolar lavage IgG titers that ranged from three-to 10-fold those of unimmunized mice. After intranasal challenge with M28 streptococci, survival of MÂ10-immunized mice was significantly higher than that of unimmunized mice. In contrast, when mice were challenged with M75 streptococci, survival of MÂ10-immunized mice did not differ significantly from that of unimmunized mice. Mx-10 immunized mice had significantly less S. pyogenes in oropharyngeal washes and developed less severe disease symptoms after challenge than did unimmunized mice. Our L. lactis-based vaccine may provide an alternative solution to development of broadly protective group A streptococcal vaccines.
infection are effectively controlled in most developed countries. However, they still occur frequently in developing countries and indigenous populations worldwide (6, 7) . Despite ongoing efforts, no vaccine for preventing these infections and their complications is currently available.
One of the most important virulence factors of this pathogen, M protein, is involved in resistance to phagocytosis through impairment of complement deposition on bacterial surfaces (8) . This protein is hypervariable in its N-terminal region, resulting in more than 200 different M protein types (9) . Antibodies produced against this hypervariable region have the greatest protective efficacy against infection (10, 11) . For this reason, M protein has been considered an attractive vaccine target (12) . However, there are safety concerns about anti-S. pyogenes vaccine development in that it is possible that such vaccines may elicit autoimmune responses in the form of acute rheumatic fever and rheumatic heart disease. Other regions of the M protein, not the hypervariable one, mimic human epitopes and are responsible for autoimmune disorders (13) . Identification of these regions has made it possible to design safer vaccines that exclude these "harmful" regions and are thus least likely to cross-react with human tissues (14) . Multivalent M protein subunit vaccines delivered parenterally have been evaluated in clinical trials and found to elicit serum antibody responses (15, 16) . Protein subunit vaccines have high production costs because the processes for manufacturing them are complex. An alternative lower cost approach involves lactic acid bacteria that express heterologous antigens (17, 18) . We have been developing an intranasal live bacterial vaccine comprising 10 strains of Lactococcus lactis, each of which expresses a different M protein fragment and have previously reported a live bacterial vaccine based on L. lactis that expresses the hypervariable region of M9 protein (19) . We have now evaluated nine additional strains of L. lactis that each express a different M protein fragment (M1, M2, M3, M4, M6, M12, M22, M28 and M77) and combined all of them into a 10-valent vaccine, MÂ10. We report here that MÂ10 vaccine elicits specific serum and mucosal antibodies against most M types included in the vaccine and protects against lethal challenge with virulent S. pyogenes M28.
MATERIALS AND METHODS

Strains, media and culture conditions
All vaccine strains were constructed using the NICE genetic system (NICE System; MoBiTech, G€ ottingen, Germany). Portions of the A domain of M protein of 41 to 50 a.a. were PCR amplified from S. pyogenes of M types 3, 6, 22 and 77 using primers with restriction enzyme sites. All strains used were clinical pharyngeal isolates. Epitopes responsible for autoimmune diseases are localized in the B domain and some regions of the A and C domains (20) . The sequences were analyzed to verify the absence of sequences resembling human proteins and therefore likely to elicit autoreactive antibodies. The portions of the A domain used to construct each vaccine correspond to the hypervariable region and are shown in Table 1 . To achieve surface display of the M protein, the hypervariable peptide was fused to 148 amino acids of the C-terminal membrane anchoring domain of M6 protein. The resulting fusion fragment was ligated to the linearized vector pNZ8149 and introduced into L. lactis strain NZ3900 through electroporation. Transformed clones were selected in M17-lactose-bromocresol purple. An L. lactis WT control strain was obtained after transformation of L. lactis strain NZ3900 with the empty plasmid pNZ8149. The presence of the plasmid bearing the insert was verified through PCR. For protein expression, recombinant L. lactis strains were grown at 30°C in M17-lactose broth supplemented with 20 ng/mL nisin. Three hours after nisin addition, the cultures were centrifuged and pellets sonicated. The resulting crude extracts were centrifuged and analyzed through 12.5% SDS-PAGE. All of the vaccine strains expressed a protein of the expected size (Fig. 1a) .
To calculate the amount of each M peptide, protein concentrations in lysates of each vaccine strain were calculated using Bradford solution (Protein Assay Solution; Bio-Rad, Hercules, CA, USA) in a microtiter plate read at 620 nm. BSA standard solutions of known concentrations (1, 1.5 and 2 mg/mL) were prepared and analyzed together with vaccine lysates in a 12.5% polyacrylamide gel with SDS. Bands of the expected molecular weight for BSA and samples were quantified through densitometry with the program Quantity One version 4.6.3 (Bio-Rad). A calibration curve was constructed with values obtained from BSA standards. The amount of recombinant M protein in each vaccine strain was extrapolated from the calibration curve and calculated with the program GraphPad Prism 5.03.
For preparation of the infective inoculum, an erythromycin-resistant S. pyogenes clinical isolate of each M type that had been previously reported (21, 22) was grown in Todd-Hewitt broth at 37°C.
Immunization and challenge of mice
All animal experiments were performed according to protocols approved by the Ethics and Biosafety Committee of the Pontificia Universidad Cat olica de Chile. For each single M type and L. lactis-WT vaccine dose preparation, 1 mL of freshly induced culture (with 20 ng/mL nisin) was centrifuged and resuspended in 50 mL of PBS, and then used to immunize one mouse. For the 10-valent vaccine, each immunization dose was divided into two doses of five different M types to facilitate manipulation and ensure appropriate immunization. Dose 1 was composed of a mixture of M1, M2, M3, M4, M6 and Dose 2 of M9, M12, M22, M28 and M77. These were prepared by mixing 1 mL of each M type, centrifuged and resuspended in 250 mL of PBS, which was then used to immunize five mice (1/5 of each M type per dose). Each mouse therefore received 2/5 of each M type. Dose 2 was administered one week after Dose 1. Groups of three or four female BALB/c mice (6 to 8 weeks-old) were intranasally immunized with 10 9 CFU of each dose on Days 0, 14 and 28. Unimmunized control mice received 50 mL of PBS. Two independent experiments of each evaluation were performed; therefore data for six to eight mice per group are shown. Twenty-one days after the third immunization, the mice were intranasally challenged with a total volume of 50 mL of PBS (25 mL in each nostril). To prevent them from swallowing the vaccine or infective dose, the mice were intraperitoneally anesthetized with a mixture of ketamine and xylazine (20 mg/kg and 1 mg/kg, respectively). Blood samples were obtained from all animals on Days 0, 28 and 49. Blood was incubated for 1 hr at 37°C and centrifuged for 5 min at 5000 rpm. Sera were transferred to a clean tube and stored at 4°C. Body weight was determined each day after challenge until the mice were killed on Day 6. Mouth washes were performed for three consecutive days after challenge by pipetting 50 mL of PBS five times up and down into the mouths of the mice and then plating the wash on blood agar supplemented with 2 mg/mL erythromycin. All of the S. pyogenes strains used in challenges were erythromycin resistant. Six days after challenge, the mice were killed and BAL performed.
Clinical severity scores were based on the most important evidence of discomfort and illness: weight loss, hypothermia, general appearance, and inability to move and react upon stimulus (23) . Balb/c mice that are ill are less reactive upon cage opening and look "wet" because they do not clean their fur (24, 25) . We used a clinical score composed of behavior, weight and general appearance, each of which was scored as 0: unaltered (healthy); 1: slightly affected; 2: affected and 3: very affected (severe illness).
Evaluation of immunogenicity
Each M type-specific IgG was determined by wholebacterial cell ELISA. S. pyogenes strains were grown overnight at 37°C/5% CO 2 in blood agar and resuspended in PBS pH 7.4 until an OD 600 of 0.34 was reached. The suspension was inactivated at 65°C for 30 min and bound to flat-bottom 96-well plates (50 mL/well) overnight at room temperature. For the peptide ELISA, synthetic peptides (5 mg/mL) (Peptide 2.0, Chantilly, VA, USA) were bound to microtiter plates in 0.1 M sodium carbonate-bicarbonate buffer, pH 9.6 (100 mL/well), overnight at room temperature. Excess bacteria or peptide were removed by five washes with PBS-T. Wells were blocked with PBS-3% BSA for 2 hr at room temperature and then washed three times with PBS-T. Mouse sera were serially diluted 1:2 with PBS-1% BSA starting from 1/100, 100 mL of each dilution then being added to the wells and incubated for 1 hr at room temperature. Mouse BALs were serially diluted 1:2 starting from undiluted fluid. Saliva was used undiluted. The wells were washed three times with PBS-T, then 100 mL of enzyme conjugate (HRP conjugated with antimouse IgG) was added and the mixture incubated for 1 hr at room temperature. Wells were then washed three times with PBS-T, 100 mL of substrate solution (3, 3 0 , 5,5;-tetramethylbenzidine; Thermo Scientific, Rockford, IL, USA) added, and the mixture incubated for 20 min in the dark at room temperature. The reaction was stopped with 100 mL H 2 SO 4 2N, and the plates read at 450 nm. The antibody titer was defined as the reciprocal of the highest dilution of serum that yielded an absorbance equal to or higher than pre-immune sera (around 0.1 at 450 nm). For saliva, the absorbance measurement is reported.
RESULTS
Vaccine construction and M protein expression
Vaccine strains expressing M1, M2, M4, M9, M12 and M28 have previously been constructed (19) , whereas vaccine strains expressing M3, M6, M22 and M77 were constructed in the present study. As shown in Figure 1a , a protein of the expected size was overexpressed by each of the 10 vaccine strains in the presence of 20 ng/mL of nisin. The amount of protein was estimated using a standard curve of known BSA concentrations. Different degrees of protein expression were found, as shown in Figure 1b . Vaccine types M9, M22, M28 and M77 showed the strongest expression.
Evaluation of efficacy of nine of the 10 vaccine strains individually
Nine of the 10 vaccines were evaluated individually in Balb/c mice that were immunized three times at 14 day intervals. Twenty-one days after the last immunization, the mice were intranasally challenged. Blood and saliva samples were obtained on Days 28 and 49. Antibody titers were determined in a whole bacterial cell ELISA assay performed according to Araya and coworkers (26) (Fig. 2) . All vaccine types induced serum IgG titers that ranged from two-to 44-fold higher than those of unimmunized mice (Fig. 2a) . Mean IgG titers in BAL were 2-15-fold higher than in unimmunized mice, the highest titers being obtained for M2 and M4 vaccine types (Fig. 2b) . Individual evaluation of vaccine types demonstrated that high serum antibody responses to individually evaluated vaccines is not always associated with high BAL antibody responses or vice versa, as observed for vaccine strains M2 and M77 (Fig. 2a, b) .
Body weight was determined for 6 days after challenge and the percentage of body weight lost is shown in Figure 3a . Weight losses of 10% were considered acceptable on the basis of reported evaluation of other vaccines in Balb/c mice (27) . Mice immunized with most of the vaccines were protected against challenge with virulent S. pyogenes as evidenced by losing significantly less body weight than unimmunized mice. Antibody response was not always associated with protection against challenge, as observed for vaccine type M22, which elicited low antibody titers (Fig. 2a) but achieved protection against infection (Fig. 3a) . Mice immunized with M3, M4, M9, M12, M22 and M28 had fewer CFU of S. pyogenes in mouth washes performed 1-3 days postinfection than did unimmunized mice (Fig. 3b) .
Evaluation of efficacy of the combined 10-valent vaccine (MÂ10)
The MÂ10 vaccine induced serum IgG titers that ranged from three-to 10-fold higher than those of unimmunized mice. M2, M6, M12 and M77 vaccine types elicited the highest serum antibody titers (Fig. 4a) . Vaccine types M6 and M2 produced low antibody titers in the individual evaluations; however their antibody titers were higher in response to the MÂ10 vaccine. In contrast, serum antibody titers for M4 and M28 were lower in MÂ10 immunized mice than in mice that received the individual vaccine components. To test the specificity of the antibodies, serum IgG titers were evaluated against two non-vaccine types, M81 and M11. Sera from mice immunized with MÂ10 elicited IgG titers against M81 and M11 that were two-to 10-fold lower than titers against most M types included in the vaccine (Fig. 4a) . These results indicate that the antibodies were for the most part directed against the M peptides expressed by the L. lactis strains. To further assess the specificity of the antibodies, sera were assayed against purified peptides. IgG titers were significantly higher in sera from MÂ10-immunized mice than in sera from unimmunized mice (Fig. 4b) . IgG antibodies were measured in BAL and found to be three-to 7-fold higher than in unimmunized mice (Fig. 4c) . IgG antibody titers were significantly higher in saliva of MÂ10-immunized mice than in saliva of unimmunized mice for types M2 and M12 (Fig. 4c, lowest table) . The volume of saliva recovered was insufficient to determine antibody titers against all vaccine M types. IgA was not detected in saliva or BAL. One group of MÂ10-immunized mice was challenged with S. pyogenes M28 (Fig. 5, left panel) and another group with S. pyogenes M75 (Fig. 5 , right panel) (M type not included in the vaccine). Oropharyngeal colonization with S. pyogenes M28 differed significantly between MÂ10-immunized and unimmunized mice 2 days post-infection: MÂ10-immunized mice were only mildly or not colonized; none of them were heavily colonized (Fig. 5a ). In contrast, around 30% of unimmunized mice were heavily colonized with S. pyogenes (Fig. 5a ). Mice immunized with MÂ10 and challenged with S. pyogenes M75 were heavily colonized by S. pyogenes (Fig. 5b) . By Day 3, most mice were mildly or not colonized. Clinical severity scores were determined after challenge and ranged from 0 (healthy) to 3 (severe illness). Figure 5c and d show that mice immunized with MÂ10 and challenged with M28 scored 2 two days after challenge, then immediately returned to a healthy score of 0. In contrast, unimmunized mice had scores of 3 until the end of the experiment. Mice immunized with L. lactis-WT reached scores of 3 on Day 2 postchallenge; their scores improved subsequently but did not return to normaly (score of 0) (Fig. 5c) . The clinical scores of unimmunized and MÂ10-immunized mice differed significantly throughout the experiment course (Fig. 5c ). Mice immunized with MÂ10 and challenged with M75 reached scores higher than 2 and did not return to normal scores, similarly to mice immunized with L. lactis-WT (Fig. 5d ). After challenge with S. pyogenes M28, survival of MÂ10-immunized mice was significantly better than that of unimmunized mice (P ¼ 0.0014) whereas survival of L. lactis WTimmunized mice did not differ significantly from that of unimmunized mice (P ¼ 0.2657) (Fig. 5e) . In contrast, when mice were challenged with S. pyogenes M75, survival of unimmunized mice did not differ significantly from that of MÂ10-immunized mice (P > 0.999) or from that of L. lactis WT-immunized mice (P > 0.999) (Fig. 5f) .
DISCUSSION
In the current study, we showed that L. lactis strains engineered to express truncated fragments of streptococcal M protein elicit immune responses in mice that confer protection against challenge infections delivered intranasally. Whether serum or mucosal antibody responses provided the greater contribution to protection is not clear. For example, the mean serum titer of anti-M28 antibodies in mice immunized with L. lactis-M28 was higher than that in mice immunized with MÂ10. Additionally, the mean BAL fluid titer of anti-M28 was $four-fold higher in mice immunized with MÂ10 than in those immunized with the L. lactis-M28 component. Yet both groups of mice showed 100% survival following challenge infections, suggesting that protection may be mediated by immune responses at either location. The amount of M protein in each vaccine dose of the individual evaluation was !10 mg, whereas the amount of each M protein in the combined MÂ10 vaccine was 2/5 of the amount used in individual tests. In spite of this, immune responses and protective efficacy were maintained, at least for M28 type. Another variable to be considered when assessing the contributions to protective efficacy of these vaccines is the observation that L. lactis alone appeared to confer some protection against challenge infections with S. pyogenes. The protection observed in L. lactis-WTimmunized mice may be attributable to the fact that intranasal administration of live bacteria, despite being "food-grade", produces a general state of inflammation that augments the innate immune response upon challenge. It is also possible that the L. lactis vector expresses surface antigens that evoke mucosal antibodies that cross-react with S. pyogenes antigens. In fact, sequence homology between these species reveals that L. lactis is closely related to S. pyogenes (28) . These results suggest that L. lactis has potential immunological value in vaccine design because their pathogen-associated molecular patterns may act as potent enhancers of innate immune responses. However, this is not enough to achieve full protection against S. pyogenes challenge, as evidenced by mice immunized with L. lactis-WT having a lower percent survival than MÂ10-immunized mice. Therefore, specific anti-M protein antibodies appear necessary for optimal protection against lethal infection in this model. It was recently demonstrated that parenteral immunization does not induce mucosal immunity or protect mice against intranasal challenge with S. pyogenes (29) . When the same antigen was administered intranasally, specific IgG and IgA were found in BAL and the mice were protected against intranasal challenge (29) . Although we did not detect IgA in MÂ10-immunized mice, we did detect significant amounts of IgG in BAL. Mucosal immunity may play an important role in protection against infection in this mouse model, independent of antibody type.
Previous studies have shown that multivalent M protein-based vaccines evoke functionally cross-reactive antibodies against a number of non-vaccine M types of S. pyogenes (30) . This observation is consistent with the new cluster-based typing system of M types that is based on sequence similarities and similar patterns of binding plasma proteins (31) . Subsequent studies have shown that M types within a cluster can be cross-opsonized by antisera against different M peptides within the same cluster (32) . In the current study, we found that mice immunized with MÂ10 vaccine were not crossprotected against S. pyogenes M75, which is a nonvaccine type from cluster E6. The MÂ10 vaccine does not contain any M proteins from cluster E6, yet it does contain four M types from cluster E4 (M2, M22, M28, and M77). It is possible that antibodies evoked by any one of these E4 cluster M proteins contributed to protection against M28 challenge infections.
The vaccine presented here potentially covers around 85% of all infections (pharyngeal and invasive) in Chile (21) and in countries with similar M-type distributions such as Mexico (33) , Argentina (34), Brazil (35) and the USA (36) . L. lactis-based vaccines may provide an alternative solution to the development of broadly protective group A streptococcal vaccines.
